Vaxcyte rockets about 50% after its 31-strain pneumonia vaccine VAX-31 hit the main goals of a Phase 3 trial in adults 50 and older, matching Pfizer's Prevnar 20 and Merck's Capvaxive on shared strains and beating them on three unique ones. Analysts call it near best case. U.S. filing planned for the first half of 2028. $PCVX @petenajarian @jonnajarian dig in because #ITSNOTANOPTION 📙 RebelCon 2026 Oct 19-21 Vegas 👉 https://t.co/3C7PXfQHvx
View on X ↗